10. $200,000,000 to Safe Schools Emergency Response to Violence Program
Endowment for the Arts - because of it
6. $300,000,000 for the Endowment for the Humanities/ because no one even knew that was a thing
7. $15,000,000 for Veterans Employment Training / for when the GI Bill isn't enough
8. $435,000,000 for mental health support

10. $200,000,000 to Safe Schools Emergency Response to Violence Program
12. $500,000,000 to Museums and Libraries / Who knows how we are going to use it
14. $25,000,000 for Cleaning supplies for the Capitol Building / I kid you not it's on page 136
15. $7,500,000 to the Smithsonian for additional salaries
17. $25,000,000 for additional salary for House of Representatives
18. $3,000,000,000 upgrade to the IT department at the VA
19. $315,000,000 for State Department Diplomatic Programs
21. $300,000,000 for International Disaster Assistance
22. $90,000,000 for the Peace Corp pg. 148
23. $13,000,000 to Howard University pg. 121
24. $9,000,000 Misc. Senate Expenses pg. 134
27. $1,000,000,000 Airlines Recycle and Save Program pg. 163
28. $25,000,000 to the FAA for administrative costs pg. 165
More from Health
This is a limited point about availability of efficacy data for vaccines under development in the context of the approval for CovidShield and Covaxin in India.
There have been many so-called experts on the idiotbox opining about apparent availability of P III data which 1/n
2/n apparently the SEC had access to based on which it "supposedly" approved Covaxin. Another argument that is prevalent is other regulators (US FDA and MHRA) also approved vaccines based on P II data alone. Let me give you a few facts so that you can make your own decision.
3/n The protocols for both mRNA vaccines are publicly available. You can check. Both protocols *define* when the interim analysis will be done. This is not subjective. They clearly define how many infections need to be documented before the Data Safety Monitoring Board meets.
4/n Find the protocols for the bridging study for CovidShield and Covaxin and look for a similar milestone.
Here is one set of efficacy data post the interim analysis of a mRNA vaccine.
Source: https://t.co/BAPnP3PxEb
5/n This data was analyzed post the interim analysis where the blind was broken by the DSMB. Now ask yourself this question:
How does the SEC, or the sponsor of these studies, or the experts who are offering their opinion liberally on the idiotbox know what the efficacy is
There have been many so-called experts on the idiotbox opining about apparent availability of P III data which 1/n
2/n apparently the SEC had access to based on which it "supposedly" approved Covaxin. Another argument that is prevalent is other regulators (US FDA and MHRA) also approved vaccines based on P II data alone. Let me give you a few facts so that you can make your own decision.
3/n The protocols for both mRNA vaccines are publicly available. You can check. Both protocols *define* when the interim analysis will be done. This is not subjective. They clearly define how many infections need to be documented before the Data Safety Monitoring Board meets.
4/n Find the protocols for the bridging study for CovidShield and Covaxin and look for a similar milestone.
Here is one set of efficacy data post the interim analysis of a mRNA vaccine.
Source: https://t.co/BAPnP3PxEb

5/n This data was analyzed post the interim analysis where the blind was broken by the DSMB. Now ask yourself this question:
How does the SEC, or the sponsor of these studies, or the experts who are offering their opinion liberally on the idiotbox know what the efficacy is